Biotechnology

Biotech R&D Overhaul: US Commission Demands Infrastructure Shift

by

Federal Commission Proposes Sweeping Changes to U.S. Research Funding Washington D.C. – A national commission has issued a comprehensive report advocating for a fundamental shift in how the United States government allocates and evaluates funding for scientific research. The recommendations, released Tuesday, prioritize streamlining grant applications and leveraging artificial intelligence, rather than simply increasing the … Read more

FDA Voucher Drug Approval: Reviewers Silenced?

by

FDA Drug Approval Process Under Scrutiny: Leadership Intervention Raises Concerns Washington – A recent shift in the Food and Drug Administration’s (FDA) process for reviewing drugs granted Commissioner’s National Priority Vouchers is sparking debate and raising questions about potential political influence. The FDA had pledged expedited reviews – typically one to two months – for … Read more

RFK Jr. & CDC: Autism-Vaccine Link Reconsidered?

by

CDC Reverses Position on Vaccine-Autism Link, Sparking Controversy WASHINGTON – In a stunning and unexpected move, the Centers for Disease Control and Prevention (CDC) has altered its publicly stated position regarding a potential connection between vaccines and autism. The change, enacted Wednesday, removes long-held assurances of no link and introduces language characterizing previous claims as … Read more

Intellia CRISPR Trial: Liver Damage & Patient Death

by

Washington, D.C. – The biotechnology landscape shifted today with a series of significant developments, including the release of a new tranche of priority review vouchers by the Food and Drug Administration and reports of a serious adverse event in a groundbreaking CRISPR clinical trial. These events, coupled with Mark Cuban’s latest venture into the biosimilar … Read more

Pfizer Sues Novo Nordisk: Merger Deal Dispute

by

Pfizer Sues Novo Nordisk in Escalating Battle for Metsera In a dramatic turn of events, Pfizer initiated legal action against Novo Nordisk and Metsera on Friday, intensifying the competition to acquire the obesity-focused biotechnology firm. The lawsuit comes just one day after Novo Nordisk launched a counter-offer, challenging Pfizer’s previously agreed-upon $4.9 billion deal. The … Read more

Alnylam Heart Drug Sales Boost Forecast & Growth

by

A staggering $8.6 billion. That’s the projected market size for treatments targeting transthyretin amyloid cardiomyopathy (ATTR-CM) by 2030, according to recent analysis. Alnylam Pharmaceuticals is not just participating in this growth; it’s rapidly becoming a dominant force, and its recent Q3 2025 earnings report confirms a trajectory that could redefine the landscape of genetic medicine. … Read more

Cancer Breakthrough: Light Therapy Kills Cells, Spares Healthy Tissue

by

Revolutionary Light Therapy Shows Promise in Eliminating Cancer Cells Without Harm to Healthy Tissue In a groundbreaking development that could redefine cancer treatment, researchers are reporting remarkable success with a novel light-based therapy. This innovative approach selectively targets and destroys cancer cells while leaving surrounding healthy tissue unharmed, offering a potentially less invasive and more … Read more

Moderna CMV Vaccine Fails Key Trial – STAT+ News

by

Moderna’s CMV Vaccine Faces Setback in Late-Stage Trial Cambridge, Massachusetts – Moderna experienced a significant hurdle Wednesday as its experimental vaccine designed to prevent cytomegalovirus (CMV) infection failed to demonstrate efficacy in a Phase 3 clinical trial. This outcome represents a substantial setback for the biotechnology firm, particularly as it navigates increased scrutiny from investors … Read more

Medicare Costs Rise: $3.9B Impact of Orphan Drug Rules

by

Washington D.C. – A recent analysis by the Congressional Budget Office (CBO) reveals the “One Big Beautiful Bill Act” is projected to cost taxpayers $8.8 billion over the next decade – a significant increase from initial estimates of $4.9 billion. The revised forecast stems from provisions within the legislation that exempt or delay Medicare price … Read more

FDA Drug Delays: Review Times & Application Backlogs Grow

by

FDA Slowdown: Drug Approvals Decline as Agency Faces Internal Challenges A recent analysis indicates a notable shift in the operational tempo of the Food and Drug Administration, potentially impacting the pharmaceutical industry’s pipeline. Key performance indicators reveal a decrease in new drug approvals during the third quarter, coupled with a rise in application rejections and … Read more

© 2026 Archyworldys. All rights reserved.

For contact, advertising, copyright, issues email: [email protected]